Pharmaceuticals group GlaxoSmithKline has launched a new $50m venture capital fund dedicated to investing in “bioelectronic medicines”, an emerging generation of neuromodulation technologies designed to treat diseases ranging from autoimmune and inflammatory conditions to respiratory disorders.
The fund, based in Cambridge, Massachusetts, is named Action Potential Venture Capital (APVC), after the electrical impulses that pass along the nerves in the body. Irregular or altered patterns of...